Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KLK7 | P49862 | 2/20 | 0.54 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17397643 | 0.91 | MAPT (0.62) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL6122027 | 0.89 | CTSK (0.52) | MAPTKLK7KLK5CTSSCTSK | |
| SCHEMBL21543552 | 0.86 | MAPT (0.57) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL31276873 | 0.86 | MAPT (0.54) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL29627360 | 0.85 | MAPT (0.56) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL21715246 | 0.85 | MAPT (0.56) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL15238738 | 0.85 | CTSK (0.48) | FOLH1CTSSCTSK | |
| SCHEMBL23357782 | 0.84 | MAPT (0.54) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL18942773 | 0.84 | MAPT (0.64) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL21715270 | 0.83 | MAPT (0.53) | MAPTKLK7KLK5ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | 7 HILLS PHARMA INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20240189360-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS PHARMA INC. (US) | 2024-06-13 | — | — | US | disclosed |
| US-11311619-B2 | Integrin activator vaccine compositions | 7 Hills Pharma Inc. and Texas Heart Institute (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3104867-B1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 Hills Pharma LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210023207-A1 | NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | 7 Hills Pharma LLC (US) | 2021-01-28 | — | — | US | disclosed |
| US-10716849-B2 | Methods of administering novel integrin activator vaccine compositions | 7 Hills Pharma LLC (US) | 2020-07-21 | — | — | US | disclosed |
| US-10709781-B2 | Integrin activator checkpoint inhibitor compositions | 7 Hills Pharma LLC (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200054600-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR SYSTEMIC TREATMENT OF SOLID TUMORS | 7 HILLS INTERESTS LLC (US) | 2020-02-20 | — | — | US | disclosed |
| US-20200054743-A1 | NOVEL INTEGRIN ACTIVATOR CHECKPOINT INHIBITOR COMPOSITIONS | 7 Hills Pharma LLC (US) | 2020-02-20 | — | — | US | disclosed |
| US-20190343952-A1 | METHODS OF ADMINISTERING NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | 7 Hills Pharma LLC (US) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311619-B2 | Integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA1 | MAPT 3555/4885KLK7 403/4885KLK5 1464/4885 |
| US-20200054743-A1 | NOVEL INTEGRIN ACTIVATOR CHECKPOINT INHIBITOR COMPOSITIONS | CD47, ITGA1, ITGA2B | MAPT 3558/4885KLK7 896/4885KLK5 2090/4885 |
| US-10709781-B2 | Integrin activator checkpoint inhibitor compositions | CD47, ITGA1, ITGAM | MAPT 3320/4885KLK7 809/4885KLK5 2008/4885 |
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | CD4, VCAM1, ITGA1 | MAPT 1861/4885KLK7 1009/4885KLK5 2006/4885 |
| US-10716849-B2 | Methods of administering novel integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA2 | MAPT 4416/4885KLK7 629/4885KLK5 1460/4885 |
| US-20190343952-A1 | METHODS OF ADMINISTERING NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | ITGAM, ITGA2B, ITGA2 | MAPT 4416/4885KLK7 629/4885KLK5 1460/4885 |
| US-20200054600-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR SYSTEMIC TREATMENT OF SOLID TUMORS | VCAM1, ITGB1, ITGA1 | MAPT 2110/4885KLK7 360/4885KLK5 689/4885 |
| US-20210023207-A1 | NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS | ITGA2B, ITGAM, ITGAV | MAPT 3756/4885KLK7 326/4885KLK5 1325/4885 |
| US-20240189360-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | CXCL12, ITGB3, ITGB7 | MAPT 4072/4885KLK7 1586/4885KLK5 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.